Price T Rowe Associates Inc Amicus Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,389,361 shares of FOLD stock, worth $13.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,389,361
Previous 1,377,358
0.87%
Holding current value
$13.8 Million
Previous $19.5 Million
16.26%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding FOLD
# of Institutions
273Shares Held
325MCall Options Held
841KPut Options Held
353K-
Vanguard Group Inc Valley Forge, PA28.2MShares$280 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$278 Million6.94% of portfolio
-
Avoro Capital Advisors LLC New York, NY27.4MShares$272 Million3.89% of portfolio
-
Black Rock Inc. New York, NY22.8MShares$227 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA18.8MShares$187 Million0.04% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.78B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...